Ziphius, une société de biotechnologie de premier plan spécialisée dans l’ARN auto-amplificateur, annonce aujourd’hui la nomination de M. Antoon Loomans au sein de son conseil d’administration
Ziphius, a biotechnology company specializing in self-amplifying RNA (saRNA), announced the appointment of Antoon Loomans to its Board of Directors. Loomans, a veteran vaccine industry executive with 30 years of experience including 27 years at GSK and recent role at VaxCo (acquired by Eli Lilly for $1.55B), will lead commercial development in the US focusing on strategic partnerships and licensing. The appointment comes as Ziphius advances its lead Chlamydia trachomatis vaccine candidate toward clinical trials and conducts a €30 million fundraising round.


